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 CURRENTOPINION Source and microenvironmental regulation
of erythropoietin in the kidney
Karen A. Nolan and Roland H. Wenger
Purpose of review
Historically, the identity of O2-sensing renal erythropoietin (Epo)-producing (REP) cells was a matter of
debate. This review summarizes how recent breakthroughs in transgenic mouse and in-situ hybridization
techniques have facilitated sensitive and specific detection of REP cells and accelerated advancements in
the understanding of the regulation of renal Epo production in health and disease.
Recent findings
REP cells are a dynamically regulated unique subpopulation of tubulointerstitial cells with features of
fibroblasts, pericytes and neurons. Under normal conditions, REP cells are located in the corticomedullary
border region within a steep decrement in O2 availability. During the progression of chronic kidney
disease (CKD), REP cells cease Epo production, dedifferentiate and contribute to the progression of renal
fibrosis. However, CKD patients with renal anaemia still respond with elevated Epo production following
treatment with hypoxia-mimicking agents.
Summary
We hypothesize that REP cells are neuron-like setpoint providers and controllers, which integrate
information about blood O2 concentration and local O2 consumption via tissue pO2, and combine these
inputs with intrinsic negative feedback loops and perhaps tubular cross-talk, converging in Epo regulation.
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chronic kidney disease, hypoxia-inducible factor, oxygen, prolyl hydroxylase inhibitor, renal anaemia
INTRODUCTION
Erythrocytes, the body’s vehicle for O2 transport, are
continuously replaced by fresh cells. Each day, 20ml
of red blood cells (RBCs) are required to replace the
approximately 120-day-old erythrocytes removed
by the reticuloendothelial system [1,2]. In the adult,
kidney-derived erythropoietin (Epo) is the essential
regulator of RBC formation not only under physio-
logical conditions but also during instances of
increased blood loss or reduced O2 saturation of
haemoglobin, for example at high altitude. Epo
signalling through its receptor promotes the sur-
vival, proliferation and differentiation of erythro-
blasts, and under chronic conditions can increase
the rate of RBC production up to 7-fold within days
[2]. Plasma Epo levels can in fact increase several
hundred folds in response to hypoxia [3]. However,
for the maintenance of a normal haematocrit and
physiological O2 homeostasis in the healthy indi-
vidual, only low basal levels of plasma Epo are
required, which is produced by a small number of
renal Epo-producing (REP) cells. Today, the connec-
tion between tissue pO2, Epo production and RBC
mass is clearly defined [2].
Epo expression is regulated almost solely at the
transcriptional level by the hypoxia-inducible factor
(HIF) pathway. HIF-regulated gene expression is
critical for the general response to hypoxia, and
HIFs ensure cellular adaptation, which protects cells
and tissues from reducedO2 availability. O2 is sensed
via O2-dependent protein hydroxylation by the
prolyl-4-hydroxylase domain (PHD) enzymes 1–3.
In the presence of O2, these enzymes hydroxylate
the HIF a subunits. Hydroxylated a subunits are
degraded by the proteasome following von Hip-
pel–Lindau (VHL)-mediated polyubiquitylation. In
addition, the factor-inhibiting HIF (FIH) attenuates
HIF transcriptional activity by asparagine hydroxyl-
ation under normoxic conditions [4]. In renal
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tubular cells, the PHD/VHL pathway mainly regu-
lates HIF-1a, which in turn controls O2 consump-
tion and energy metabolism. In cortical interstitial
cells, following a decrease in arterial O2 concentra-
tion, HIF-2a is stabilized and induces Epo gene
expression [5]. Indeed, conditional knockout of
HIF-2a in adult mice results in anemia, whereas loss
of HIF-1a does not [6]. Among the many hundreds
of HIF target genes, Epo is regulated with particular
sensitivity. In hypoxia, HIF-2a regulates a rapid and
robust Epo mRNA induction, which decreases
despite ongoing hypoxia [7,8]. This is in contrast
to the delayed and prolonged HIF-2a expression
commonly observed in cancer cell lines [9], and
suggests a unique regulation of HIF-2a in REP cells.
PHDs are HIF targets themselves and are likely
involved in the negative feedback on Epo mRNA
expression as reported previously for other HIF
target genes in cancer cells [10].
ERYTHROPOIETIN PRODUCTION: WHY
THE ADULT KIDNEY?
In the developing embryo, the liver is responsible for
the production of circulating Epo. Epo and EpoR
knockout mice die in utero, highlighting the impor-
tance of Epo in normal development [11,12]. Post-
natally, a switch in the site of Epo production
occurs, with the kidney becoming the predominant
organ for Epo production, accounting for approxi-
mately 90% of total Epo synthesis in the adult [2].
Under physiological conditions, the ratio between
renal O2 supply and consumption stays within a
relatively narrow range. Unlike other organs, which
experience enhanced tissue oxygenation upon
increased blood flow, the kidney does not. The
reason for this is the tight matching between
glomerular filtration rate (GFR) and transport pro-
cesses. Increasing renal blood flow (i.e. more O2
supply) increases GFR and reabsorption (i.e. more
O2 demand). The resulting relatively stable oxygen-
ation makes the kidney a superior organ for sensing
decreases in tissue pO2 caused by decreased bloodO2
concentration [4,13]. However, it should be noted
that if the O2-carrying capacity of the blood
increases, it does result in improved oxygenation,
even at constant renal blood flow. A recent study by
Dimke et al. [14] highlighted the importance of
appropriate kidney perfusion and hence, oxygen-
ation in renal Epo expression using a mouse model
lacking tubular VEGFA. These mice developed
smaller kidneys with a decreased density of peritub-
ular capillaries and were polycythaemic because of
enhanced renal Epo production. Although other
organs such as the liver, brain, testes, uterus and
adrenal glands have also been reported to produce
Epo in the adult, they contribute only to a minor
degree to circulating Epo [15–18,19
&
].
RENAL ERYTHROPOIETIN-PRODUCING
CELLS: INSIGHTS FROM GENETICALLY
MODIFIED MICE
The first undisputable evidence that REP cells are a
population of interstitial cells found mainly in the
cortex and the outermedulla came with the dawn of
genetically modified mice. In 1993, Maxwell et al.
[20] generated a mouse in which the Epo locus
directed the expression of the marker gene SV40
T-antigen, which could be subsequently detected
by immunohistochemical techniques. More recent
developments, including the generation of fluores-
cent reporter mice using bacterial artificial chromo-
somes (BACs) of approximately 200 kb length as
well as novel in-situ hybridization methods, have
advanced the understanding of the REP cell popula-
tion and further confirmed these initial in-vivo
findings. Obara et al. [21] generated a transgenic
mouse using a BAC clone in which the region span-
ning exon II to intron IV of the Epo gene was
replaced with a green fluorescent protein (GFP)
reporter gene. Consistent with the observations by
Maxwell and colleagues, Obara et al. identified a
GFP-positive sub-population of peritubular intersti-
tial cells induced under anaemic conditions. Inter-
estingly, these cells have dendrite-like processes and
show features of neuronal cells, including the
expression of MAP2 and NFL, as well as fibroblast
markers CD73 and PDGFR-b [21,22]. Although this
model was useful for the investigation of cells
acutely producing Epo, the fate of these cells over
time cannot be investigated, as the GFP expression is
limited to the timeframe of active Epo transcription.
In another approach to identify REPs, GFP cDNA
was introduced into the endogenous Epo locus,
KEY POINTS
 Renal Epo-producing (REP) cells are a subpopulation of
cortical tubulointerstitial cells, sense drops in tissue pO2
and respond with increased Epo expression.
 Genetic tagging and novel in-situ hybridization
techniques unequivocally demonstrated that REP cells
share features of fibroblasts, pericytes and neurons.
 Mouse models targeting REP cells demonstrate their
contribution to the progression of renal fibrosis in CKD.
 Pharmacological activation of the HIF-pathway reverses
loss of Epo production in CKD and is an attractive
therapeutic option for the treatment of renal anaemia.
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confirming the phenotype observed previously [23].
Finally, a recently developed improved in-situ
hybridization technique revealed a fully consistent
REP cell-staining pattern based on endogenous Epo
mRNA [19
&
,24
&
].
Under genetically induced severe anaemic con-
ditions, the majority of interstitial cortical fibro-
blasts produce Epo, as shown by Yamazaki et al.
[25] using an Epo-Cre BAC transgene crossed to a
tdTomato reporter mouse. However, at a given time
point, only 10% of these cells are actively transcrib-
ing Epo. Similarly, whenever VHL is deleted in
PDGFRb-expressing interstitial cells, virtually all
cells do express Epo [19
&
]. Of note, genetic deletion
of VHL from normally non-Epo producing cells also
leads to Epo expression [26,27]. The physiological
relevance of such genetic models, which artificially
induce permanent and severe changes, has to be
carefully considered as they fail to recapitulate the
rather mild and transient physiological stimuli and
the changing environment regulating the cellular
hypoxic response.
Most recently, Epo-producing cells in the adult
mouse kidney were found to be derived from FoxD1-
expressing stromal cells. FoxD1 is expressed by
the developing (but not the adult) kidney, and gives
rise to cortical and medullary renal interstitial
fibroblasts, pericytes, mesangial cells and vascular
smooth muscle cells. Epo knockout in FoxD1-
expressing cells had no impact on mouse develop-
ment. However, these mice go on to develop hypo-
proliferative anaemia [24
&
]. Furthermore, thesemice
showed no kidney Epo induction following expo-
sure to 10% O2 for 2 days or following treatment
with the PHD inhibitor (PHI) GSK1002083A. The
authors suggest that the small increase in serum Epo
observed in PHI-treated mice is likely a result of
liver-derived Epo. These data reveal that the relevant
REP cell population is contained within the FoxD1-
derived cell population. Interestingly, the FoxD1
population was found to be heterogeneous in that
not all FoxD1-derived cells respond to Epo-inducing
stimuli with Epo production. It was suggested that
the different capacities for Epo production among
the cells may be dependent on the PHD2 and
PHD3 levels.
Together these studies unequivocally confirm
the localization of REP cells in the deep juxtame-
dullay cortex under normal physiological condi-
tions. This population expands to include more
superficially located tubular interstitial cells under
conditions of reduced tissue pO2 (Fig. 1). However,
REP cells fail to produce sufficient Epo to maintain
a normal haematocrit in chronic kidney disease
(CKD) patients.
RENAL ERYTHROPOIETIN-PRODUCING
CELLS AND ERYTHROPOIETIN
PRODUCTION IN CHRONIC KIDNEY
DISEASE
Renal anaemia because of Epo insufficiency is a
common complication of CKD, which increases in
prevalence with the decline in estimated GFR
FIGURE 1. Schematic illustrating the location of renal erythropoietin-producing cells between the medullary and cortical areas.
REP cells (brown; counterstained by hematoxylin, blue) were detected by Epo mRNA in-situ hybridization following exposure
of a mouse to 0.1% carbon monoxide for 4 h, resulting in approximately 50% HbCO. Hypothetical tissue pO2 profiles are
indicated, including possible left and right shifts under conditions of increased or decreased, respectively, renal oxygenation.
Whereas a right shift leads to the recruitment of additional REP cells, a left shift leads to the loss of Epo production as the
medulla does not contain REP cells. Epo, erythropoietin; REP, renal erythropoietin-producing.
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(eGFR), with over 50% of stage-5 CKD patients being
anaemic [28]. Anaemic patients with normal renal
function have 10–100-fold higher plasma Epo con-
centrations compared with anaemic CKD patients
[29,30], supporting the idea that kidney Epo is
the predominant source of circulating Epo in the
adult human.
There are two apparently contradicting hypoth-
eses explaining Epo dysregulation in CKD. On one
hand, dedifferentiation of REP cells might cause a
transient or permanent loss of Epo production
despite lowered tissue oxygenation (e.g. because
of vascular injury and/or fibrotic tissue remodel-
ling). As discussed further in the following, perivas-
cular cells, including REP cells are thought to be the
precursors of myofibroblasts in CKD [31,32,33
&
,34].
On the other hand, the reduced energy require-
ments of dysfunctional nephrons cause relative
hyperoxia, HIFa degradation and ceased Epo pro-
duction. In this case, we assume that REP cells do not
lose their ability to produce Epo per se, but exist in a
microenvironment which no longer supports Epo
production. Interestingly, patients with kidney fail-
ure living at high-altitude require lower doses of
recombinant Epo [35] and dialysis patients respond
with increased Epo production to PHI treatment
[36], demonstrating that the diseased kidney main-
tains the potential to express Epo. In addition to
dedifferentiation and hyperoxia also other currently
unknown tubular signals and reversible dedifferen-
tiation might be involved in dysregulated Epo
expression by REP cells. Recently, a role for tubular
HIF-1a in Epo insufficiency has been proposed,
suggesting a more complex crosstalk in the tubu-
lointerstitial microenvironment [37].
Similar to these seemingly contradictory
hypotheses for Epo insufficiency, the role of HIF
in CKD and the progression of renal fibrosis is
equally debated [38]. Evidence supports both pro-
tective as well as deleterious mechanisms of HIF,
despite the fact that HIF clearly fails to induce renal
Epo under these conditions. The conflicting find-
ings likely reflect a very tightly regulated cell and
context-specific function of HIF, which makes it
difficult to define its exact role in CKD. Evidence
to date is based on single snap shots of the complex
pathway of disease progression and likely fails to
reflect the dynamic HIF regulation.
In a recent study, a group of CKD patients with
moderate anaemia was found to have higher Epo
levels than healthy controls. de Seigneux et al. [39]
demonstrated that Epo derived from these patients
exhibits a different glycosylation pattern compared
with Epo derived from healthy controls, but similar
to the pattern of Epo derived from umbilical
cord blood, which is considered hepatic in origin.
These data suggest that although compensating for
reduced circulating Epo, liver-derived Epo fails to
correct renal anaemia.
In mouse models of renal injury, REP cells have
been shown to transform into extracellular matrix
producing myofibroblasts and contribute to the
progression of renal fibrosis. Genetically tagged
REP cells have been found to express the myofibro-
blast marker a-SMA in fibrotic but not in healthy
kidneys [22,32,40]. The FoxD1 population of cells,
reported to include REP cells [24
&
], has previously
been shown to be the predominant source of a-SMA-
positive myofibroblasts, causing renal fibrosis
[31,41]. Importantly, thesemyofibroblasts maintain
the plasticity to resume Epo production, following
removal of the injury-triggering stimulus or suppres-
sion of inflammation [32]. Also PHD2 knockout
rescued Epo production but had no protective effect
against the progression of renal fibrosis [33
&
]. Inter-
estingly, under disease conditions, the long REP cell
processes, which are normally tightly wrapped
around the capillaries, detach from the vessels
and associate with adjacent tubules [33
&
].
The role of O2 (re-)distribution, however, if any,
in the REP-myofibroblast differentiation balance is
currently unclear because of technical limitations
in determining the tissue pO2 profiles at high
resolution [42].
TARGETING THE OXYGEN-SENSING
PATHWAY FOR THERAPY
Current therapy for patients with renal anaemia
requires the chronic subcutaneous injection of
recombinant human Epo, which is associated with
increased blood pressure and cardiovascular risk
[43]. Not surprisingly, the O2-sensing pathway is
an attractive target for the treatment of renal anae-
mia. In the last decade, small molecule HIF-stabiliz-
ing PHIs have been developed, aiming for an oral
therapy enhancing endogenous Epo production.
Several PHIs are currently in phase III clinical trials
[44,45]. In addition to Epo stimulation, these com-
pounds also have beneficial effects on iron metabo-
lism. In contrast to sub-cutaneous recombinant Epo
application, which results in peaks in plasma Epo
concentration and may underlie adverse outcomes
[46], PHI treatment results in smaller fluctuations in
plasma Epo levels [47–49]. Long-term treatment of
mice and rats with the PHI FG-4592/roxadustat has
no effect on the development of neoplastic lesions
[50] and does not promote tumour initiation, pro-
gression or metastasis in a VEGF-sensitive model of
spontaneous breast cancer [51]. However, a cautious
outlook remains until the potential nonerythro-
poietic side effects because of activation of the
Renal Pathophysiology
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HIF or other pathways [52] have been thoroughly
addressed.
CONCLUSION
Historic disputes over the cell type responsible for
the synthesis of kidney-derived Epo have truly been
put to rest in the age of genetically modified mice
and reliable in-situ hybridization techniques, which
reproducibly identify a subpopulation of tubuloin-
terstitial cells as REPs (Fig. 1). However, identifying
unique characteristics of these cells, which separates
them from the heterogeneous interstitial cell popu-
lation has proven an exceptional challenge. Efforts
are required to understand the microenvironmental
changes that contribute to Epo suppression in CKD
and likely involve the dysregulation of the HIF
pathway in REP cells as well as their de-differentia-
tion. Emerging therapies targeting the O2-sensing
pathway offer hope of an oral therapy for anaemic
CKD patients and may be harnessed for therapeutic
effects beyond the stimulation of renal Epo expres-
sion, including anti-inflammatory and antifibrotic
effects.
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